WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
Conjugation and Payload-Linker Technology Innovation
Turn Transformative Potential into Reality
The path to ADC success demands precision—from DAR optimization and linker stability to rigorous safety profiling. At WuXi XDC, we recognize the transformative potential of bioconjugates and are committed to turning promise into reality. Leveraging our proprietary technologies, we have built a robust foundation for advanced bioconjugate development. Beyond our internal capabilities, we are actively forging and expanding partnerships with leading industry players. Through these collaborations, we continuously enrich and refine our technology platform, we don’t just support your journey—we propel it forward, accelerating breakthroughs at every stage.
WuXiDARx™, our proprietary conjugation technology targeting the clinically validated interchain cysteine sites, delivers exceptional flexibility in drug-to-antibody ratio (DAR) and demonstrates high homogeneity. It is compatible with native IgG1 antibodies and a wide range of common payload linker and significantly simplifies the CMC process.
The technology delivers significant value across the development continuum: when screening antibody and payload-linker combinations, it streamlines ADC engineering and facilitates optimal DAR identification. At the CMC stage, it accelerates development, mitigates risks, and reduces large-scale manufacturing costs.
Features and Advantages
Enable Versatility across Diversified Bioconjugates beyond Conventional ADCs
Robust and Validated Conjugation Technology
ADCs produced from WuXiDAR4 demonstrated comparable cytotoxicity to ADCs produced by conventional random conjugation methods, but demonstrate better pharmacokinetics (PK) profiles and tolerability. So far, 7 ADC molecules that WuXiDAR4 has generated have entered clinical trials.
Improved Efficacy and Tolerability
WuXiDAR4 technology features an enhanced high-homogeneity DAR 4 profile. ADCs engineered with the technology demonstrate superior PK and in vivo efficacy relative to ADCs achieving DAR 4 via conventional random cysteine conjugation.
Simple and Robust CMC
CMC projects
Clinicla-stage ADC molecules
GMP batches prepared
Ideal for Your Antibody-Oligonucleotide Conjugates
- High purity: Up to ~ 90% D1 species before column purification
- Simple process: Chemical conjugation, comparable with symmetrical antibody, no sequence engineering or enzymatic reaction required
- Good efficacy: Higher siRNA in target tissue and stronger DMPK silence efficiency in mouse
The commonly employed maleimide-thiol conjugation in ADCs is susceptible to retro-Michael addition—a reversible reaction that leads to compromised efficacy and off-target toxicity. WuXi XDC addresses this inherent instability through our proprietary X-LinC connector technology. This innovative solution has demonstrated superior plasma stability, high conjugation efficiency, and seamless compatibility with WuXiDARx.
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?